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The molecular mechanism for blood vessel 
development in tumors has been an area of in-
tense study in recent decades. The function of 
prototypical angiogenic factors, such as vascular 
endothelial growth factor (VEGF) A, placental 
growth factor, basic fibroblast growth factor 
(bFGF), and platelet-derived growth factors 
(PDGFs), has been elucidated in great detail 
(Pietras et al., 2003; Rusnati and Presta, 2007; 
Ellis and Hicklin, 2008). The large knowledge 
base has resulted in the development of several 
targeted therapeutics aimed at limiting the for-
mation of new blood vessels within tumors by 
neutralizing or inhibiting the action of angio-
genic factors, including bevacizumab (an anti-
VEGF antibody) and multireceptor tyrosine 
kinase inhibitors such as sunitinib, sorafenib, and 
imatinib (Pourgholami and Morris, 2008). How-
ever, development of new and more effective 
drugs aimed at targets complementary to the ones 
currently available for anti-angiogenic therapy 
is highly desirable.
The TGF- superfamily consists of >30 se-
creted cytokines in mammals, including TGF-s, 
bone morphogenetic proteins (BMPs), activins, 
and  growth  and  differentiation  factors.  The 
family members perform diverse but important 
actions in embryogenesis and pathogenesis, in-
cluding angiogenesis and cancer (Pardali and 
Moustakas,  2007;  Schmierer  and  Hill,  2007; 
ten Dijke and Arthur, 2007). Cellular signaling 
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Members of the transforming growth factor  (TGF-) family have been genetically linked 
to vascular formation during embryogenesis. However, contradictory studies about the role 
of TGF- and other family members with reported vascular functions, such as bone mor-
phogenetic protein (BMP) 9, in physiological and pathological angiogenesis make the need 
for mechanistic studies apparent. We demonstrate, by genetic and pharmacological means, 
that the TGF- and BMP9 receptor activin receptor-like kinase (ALK) 1 represents a new 
therapeutic target for tumor angiogenesis. Diminution of ALK1 gene dosage or systemic 
treatment with the ALK1-Fc fusion protein RAP-041 retarded tumor growth and progres-
sion by inhibition of angiogenesis in a transgenic mouse model of multistep tumorigenesis. 
Furthermore, RAP-041 significantly impaired the in vitro and in vivo angiogenic response 
toward vascular endothelial growth factor A and basic fibroblast growth factor. In seeking 
the mechanism for the observed effects, we uncovered an unexpected signaling synergy 
between TGF- and BMP9, through which the combined action of the two factors aug-
mented the endothelial cell response to angiogenic stimuli. We delineate a decisive role for 
signaling by TGF- family members in tumor angiogenesis and offer mechanistic insight for 
the forthcoming clinical development of drugs blocking ALK1 in oncology.
© 2010 Cunha et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it  is  available  under  a  Creative  Commons  License  (Attribution–Noncommer-
cial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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studies using well characterized in vivo models of angiogene-
sis and tumorigenesis.
In this paper, we demonstrate that the TGF- family type I   
receptor ALK1 provides a viable new target for tumor angio-
genesis. Strikingly, blunted ALK1 expression or signaling by 
genetic or pharmacological means delayed activation of the 
angiogenic switch and inhibited the growth of fully grown 
tumors. In seeking the molecular mechanism for the observed 
effects, we found an unexpected synergistic effect of TGF- 
and BMP9 in stimulation of ALK1-dependent endothelial 
cell growth and sprouting in response to angiogenic stimuli. 
Our results provide mechanistic insight for the ALK1 targeting 
agents presently being introduced in patients and encourage 
the addition of molecular profiling and anti-angiogenic end 
points to the clinical trial designs.
RESULTS
BMP9 and TGF- expression is increased during the tumor 
progression pathway of the RIP1-Tag2 model
The RIP1-Tag2 mouse model of endocrine pancreatic tumor-
igenesis has been widely studied (Hanahan, 1985). Because 
its multistep progression through a synchronous angiogenesis-
dependent pathway from normal pancreatic islets to hy-
perplastic islets, angiogenic islets, and, finally, into overt 
insulinomas and because of its proven predictive value for as-
sessing possible targets for anti-angiogenic therapies (Bergers 
et al., 1999), it constitutes a suitable model for investigating 
the role of TGF- signaling in tumor angiogenesis. First, we 
determined the expression pattern of key ligands and recep-
tors in the TGF- signaling pathways during RIP1-Tag2 
tumorigenesis. As judged by quantitative RT-PCR analysis, 
the expression of ALK1 was significantly increased in angio-
genic islets from RIP1-Tag2 mice, as compared with other 
stages of normal or malignant islets (Fig. 1 a). Consistent with 
the reported endothelial cell–restricted expression of ALK1 
(Roelen et al., 1997), other vascular markers, including CD31 
and vascular endothelial cadherin, demonstrated a similar pat-
tern of expression (Fig. S1, a and b). In contrast, the expres-
sion of ALK5 was comparatively low and remained unchanged 
during  the  tumorigenesis  pathway  of  RIP1-Tag2  mice 
(Fig. 1 b). Further analysis of the TC3 cell line established 
from a RIP1-Tag2 tumor (Efrat et al., 1988) revealed that 
tumor cells express high levels of ALK5 but not of ALK1 
(Fig. S1 c). Notably, the messenger RNA (mRNA) of both 
TGF- and BMP9 were present at dramatically increasing levels 
during the course of malignant progression in RIP1-Tag2 
mice and were expressed at 5.2- and 4.4-fold higher levels in 
tumors compared with normal islets, respectively (Fig. 1, c 
and d). Expression of the ALK1 ligand BMP10 was up-regulated 
in angiogenic islets, albeit to a lower degree, but decreased to 
baseline levels in tumors (Fig. S1 d). The TC3 cell line ex-
pressed high levels of both TGF- and BMP9 but negligible 
amounts of BMP10 (Fig. S1 e). Given the structural similarity 
between BMP9 and BMP10, it is likely that the two ligands 
share many properties, so our subsequent efforts were focused 
on BMP9.
is initialized by ligand-induced heterotetrameric complex for-
mation of type I and type II receptors. The prototypical li-
gand TGF-1 (hereafter referred to as TGF-) binds to the 
TGF- type II receptor (TGF-RII), with subsequent re-
cruitment of its type I receptors, e.g. the ubiquitously expressed 
activin receptor-like kinase (ALK) 5. After phosphorylation 
of the type I receptor by the type II receptor, downstream 
signaling is initiated by phosphorylation and activation of 
Smad transcription factors that control expression of target 
genes in a manner specific to type I receptor and cell-type; 
moreover, non-Smad pathways that modulate Smad and other 
major signaling pathways are initiated (Shi and Massagué, 
2003; Moustakas and Heldin, 2005). In addition to intricate 
ligand-receptor combinations, more complexity is added by 
the existence of membrane-bound and soluble forms of acces-
sory receptors, such as endoglin and betaglycan, which harbor 
the potential to modulate signaling specificity and intensity.
Members of the TGF- family have been previously im-
plicated in vasculogenic and angiogenic processes, mostly 
through genetic studies of mice (Seoane, 2008; Goumans 
et al., 2009). Germline mutations in the TGF- type I receptor 
ALK1 (ACVRL1) or the accessory receptor endoglin (ENG)   
are  causal  in  the  development  of  the  human  syndrome   
hereditary hemorrhagic telangiectasia (HHT), which is char-
acterized by telangiectases, hemorrhages, and arterio-venous   
malformations (Sadick et al., 2006). Although Alk1 or Eng 
knockout mice are embryonic lethal as a result of severe vas-
cular malformations (Arthur et al., 2000; Oh et al., 2000), 
mice lacking one copy of the gene for either ALK1 (Alk1+/ 
mice) or Eng recapitulate the HHT phenotype with age 
(Srinivasan et al., 2003; Torsney et al., 2003). Despite the ge-
netic evidence, the exact role for TGF- signaling in angio-
genesis has proved elusive. TGF- may engage either the 
ubiquitously expressed type I receptor ALK5 or the predom-
inantly vascular receptor ALK1 in endothelial cells. Although 
most studies find that ALK5 receptor activation inhibits en-
dothelial cell migration, proliferation, and tube formation 
and that ALK1 receptor activation promotes the same pro-
cesses (Goumans et al., 2002; Wu et al., 2006), there are also 
results indicating that endothelial cell function can be inhib-
ited by constitutively active ALK1 receptors (Lamouille et al., 
2002; David et al., 2007). Moreover, despite seemingly 
opposing roles on endothelial cells after stimulation with 
TGF-, ALK5 receptors are obligatory for appropriate ALK1 
receptor function because endothelial cells deficient for ALK5 
do not induce proper TGF-/ALK1 signaling (Goumans et al., 
2003b). Furthermore, recent studies describe BMP9 and 
BMP10 as high-affinity ligands for ALK1 (David et al., 2007; 
Scharpfenecker et al., 2007). In contrast to TGF-, signaling 
induced by BMP9 through ALK1 results in inhibition of both 
VEGF- and FGF-induced angiogenesis in vitro (David et al., 
2007; Scharpfenecker et al., 2007). Finally, ALK1 is expressed 
mainly at sites of angiogenesis during embryogenesis (Roelen 
et al., 1997), but the abundance and function of ALK1 during 
tumor angiogenesis is largely unchartered. Clearly, there is a 
need for resolution of the apparent paradoxes by mechanistic JEM VOL. 207, January 18, 2010 
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Figure 1.  BMP9 and TGF- signaling is increased during the tumor progression pathway of the RIP1-Tag2 model. (a–d) Quantitative RT-PCR 
analysis of the expression of ALK1 (a) and ALK5 (b) receptors and TGF- (c) and BMP9 (d) ligands in pancreatic islets from progressive tumor stages in 
RIP1-Tag2 mice (materials pooled from >20 mice per tumor stage, analysis independently performed at least three times). Error bars show the mean ± SD. 
(e–h) Immunostaining for ALK1 (red; e), ALK5 (red; f), TGF- (red; g), and BMP9 (red; h) of sections from the pancreas of RIP1-Tag2 mice. As a compari-
son, immunostaining for the endothelial cell marker podocalyxin (green) was performed in e and for CD31 (green) in f. The angiogenic islet lesional area is 
outlined by white dashes. Bars, 50 µm.88 Targeting of ALK1 impairs tumor growth | Cunha et al.
ALK1  expression.  The  vascular  density,  as  revealed  by   
immunostaining for the endothelial cell marker CD31, was sig-
nificantly  lower  in  pancreatic  lesions  from  RIP1-Tag2; 
Alk1+/  mice  compared  with  RIP1-Tag2;  Alk1wt  mice 
(Fig. 2 e, P < 0.05). The diminished vascular tree resulted in 
an overall reduction in vascular perfusion of angiogenic islets 
and tumors by 59% in RIP1-Tag2; Alk1+/ mice (Fig. 2 e,   
P < 0.01). Collectively, we conclusively demonstrate that 
genetically blunted ALK1 expression retards tumor progres-
sion through the angiogenic switch, reduces de novo tumor 
growth, and impairs angiogenesis in the RIP1-Tag2 model 
of pancreatic islet carcinomas.
RAP-041 neutralizes BMP9 activity and inhibits angiogenic 
sprouting in vitro and in vivo
To assess whether ALK1 represents a valid therapeutic target 
for tumor angiogenesis, we made use of the signal transduc-
tion inhibitor RAP-041. RAP-041 is a fusion protein com-
prised of portions of the extracellular domain of mouse ALK1 
fused to the Fc portion of IgG1. First, we determined the 
neutralizing capacity and specificity of RAP-041 in vitro using 
luciferase reporter constructs. All ligands evaluated, including 
TGF-, BMP9, and BMP10, readily activated transcription 
after stimulation of C2C12 cells transfected with the respec-
tive reporter constructs. BRE-luc was used for ALK1 activa-
tion and CAGA-luc was used for ALK5 activation (Dennler 
et al., 1998; Korchynskyi and ten Dijke, 2002; Fig. 3, a–c). 
RAP-041 potently suppressed the transcriptional activation 
induced by BMP9 and BMP10 (Fig. 3, a and b), in accor-
dance  with  previous  results  showing  that  BMP9  and 
BMP10 are high-affinity ligands for ALK1 (David et al., 2007; 
Scharpfenecker et al., 2007). TGF-–induced transcriptional 
activity was not neutralized by RAP-041, which is consistent 
with the notion that TGF- does not bind ALK1 in the 
absence of TGF-RII and ALK5 (Goumans et al., 2003b; 
Fig. 3 c). Consistent with these findings, RAP-041 strongly 
inhibited  BMP9-induced  Smad1  phosphorylation  but  not 
TGF-–induced Smad2/3 phosphorylation in cell culture ex-
periments (Fig. 3 d).
Next, we sought to analyze the inhibitory effects of RAP-
041 on endothelial cell function and physiological angiogenesis. 
First, we seeded human umbilical vein endothelial cells 
(HUVECs) on Matrigel-coated plates to examine the effects 
of RAP-041 on endothelial cord formation. RAP-041 signif-
icantly suppressed the combined length of the resulting endo-
thelial cell cords by 42%, as compared with control Fc protein 
(Fig. 3 e, P < 0.05). Also, when applied to a three-dimensional 
endothelial cell spheroid sprouting assay using HUVEC, 
RAP-041 significantly reduced VEGF-induced sprouting 
(Fig. 3 f, P < 0.001). Finally, RAP-041 significantly impaired 
the VEGF-A and/or bFGF-induced in-growth of blood ves-
sels into subcutaneously injected Matrigel plugs in mice, com-
pared with control Fc (Fig. 3 g, P < 0.0001; and Fig. S3, P < 
0.01). We conclude that RAP-041 potently and specifically 
inhibits BMP9 and BMP10 activity, resulting in an impaired 
angiogenic response toward VEGF and bFGF.
Next, we made use of immunostaining to ascertain which 
cell types expressed ALK1, ALK5, BMP9, and TGF- in RIP1-
Tag2 tumors. The specificity of the staining pattern was ascer-
tained by omission of the primary antibody (unpublished data). 
As seen in Fig. 1 e, ALK1 was exclusively expressed by endo-
thelial cells, which is in agreement with the RT-PCR analysis. 
The common TGF- type I receptor ALK5 was expressed by 
the tumor cells of RIP1-Tag2 lesions at low levels but to a 
substantially higher degree by infiltrating cells in the tumor 
border, most likely representing inflammatory cells (Fig. 1 f). 
TGF- expression was detected throughout the angiogenic and 
tumor lesions, most notably in the -cells (Fig. 1 g). Finally, 
BMP9 was exclusively and prominently represented in the   
endocrine pancreas, specifically by the tumorous -cells, and 
was absent from the surrounding exocrine tissue (Fig. 1 h).
Blunted ALK1 signaling retards the angiogenic switch  
and tumor growth in the RIP1-Tag2 model
Having documented an increased expression of TGF- and 
BMP9 by malignant  cells during the tumor progression 
pathway of RIP1-Tag2 mice, we next sought to analyze the 
consequences of genetically reduced expression of their 
receptor ALK1. Accordingly, we crossed RIP1-Tag2 mice 
with mice deficient for one copy of ALK1 (RIP1-Tag2; 
Alk1+/ mice). Alk1 +/ mice are born seemingly normal but 
develop vascular lesions in the skin, oral cavity, lung, liver, 
intestine, spleen, and brain with age (Srinivasan et al., 2003). 
However, no phenotype was noted in the pancreas, and the 
earliest time of detection for vascular abnormalities was 7 mo, 
i.e., a considerable time after our analysis was completed. The 
phenotype of RIP1-Tag2; Alk1+/ mice was compared with 
that of WT littermate RIP1-Tag2 mice (RIP1-Tag2; Alk1wt 
mice). As expected, tumors from RIP1-Tag2; Alk1+/ mice 
exhibited an 50% reduction in the expression of ALK1, as 
compared with tumors from RIP1-Tag2; Alk1wt mice (Fig. 2 a). 
Interestingly, the expression of ALK5 and the accessory 
receptor endoglin was similarly reduced in tumors from 
RIP1-Tag2; Alk1+/ mice compared with tumors from WT 
mice (Fig. S2, a and b). Next, we assessed the effect of re-
duced ALK1 expression on the activation of the angiogenic 
switch by quantifying the number of angiogenic islets ob-
served under a stereological microscope in the pancreata excised 
from 12-wk-old RIP1-Tag2 mice. Strikingly, RIP1-Tag2; 
Alk1+/ mice displayed a 50% reduction in the number of 
overtly angiogenic islets compared with RIP1-Tag2; Alk1wt 
mice (Fig. 2 b, P < 0.0001). Consistent with the reduced 
number of premalignant lesions, RIP1-Tag2; Alk1+/ mice 
presented with a mean of 1.55 ± 1.36 tumors per pancreas, 
representing a 56% reduction compared with RIP1-Tag2; 
Alk1wt mice, which developed a mean of 3.52 ± 1.78 tumors 
at 12 wk of age (Fig. 2 c, P < 0.001). Furthermore, the total 
tumor volume per mouse was significantly reduced from 42.5 
± 23.9 mm3 in RIP1-Tag2; Alk1wt mice to 23.1 ± 28.2 mm3 
in RIP1-Tag2; Alk1+/ mice (Fig. 2 d, P < 0.01).
Subsequently, we sought to determine the phenotypic 
changes in the vascular tree as a consequence of the blunted JEM VOL. 207, January 18, 2010 
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Figure 2.  Blunted ALK1 signaling retards the angiogenic switch and tumor growth in the RIP1-Tag2 model. (a) Quantitative RT-PCR analysis of 
the expression of ALK1 in tumors from RIP1-Tag2; Alk1+/ mice compared with that of WT littermates (analysis independently performed at least three 
times). (b–d) Quantification of the number of angiogenic islets (b), the number of tumors (c), and total tumor burden (d) in RIP1-Tag2; Alk1wt mice and 
RIP1-Tag2; Alk1+/ mice. Box boundaries represent the interquartile range and the bars represent the full range. Solid and dotted line represents median 
and mean tumor volume, respectively. Circles denote statistical outliers (mean ± 2 SD). (e) Quantification of the vascular density, total (by CD31 immuno-
staining), and vessels perfused (by FITC-conjugated lectin), as a percentage of the lesional area, both in RIP1-Tag2; Alk1wt mice and RIP1-Tag2; Alk1+/ 
mice (n = 5 mice for each analysis; CD31, red; FITC-lectin, green). Error bars show the mean ± SD. Bars, 50 µm.90 Targeting of ALK1 impairs tumor growth | Cunha et al.
Figure 3.  RAP-041 neutralizes BMP9 activity and inhibits angiogenic sprouting in vitro and in vivo. (a–c) Assessment of the capacity of RAP-
041 to neutralize BMP9 (a), BMP10 (b), and TGF- (c) by transcription activation luciferase reporter assays in C2C12 cells. Normalized promoter activity is 
plotted in arbitrary units as mean values from triplicate determinations (analyses independently performed at least three times). (d) Immunoblot analysis 
of the neutralizing activity of RAP-041 on BMP9-induced phosphorylation of Smad1 (pSmad1) in HUVEC (top) and on TGF-–induced phosphorylation  
of Smad2 (pSmad2) and Smad3 (pSmad3) in C2C12 cells (bottom; analyses independently performed at least three times). The antibody used to detect 
pSmad3 (bottom band) also reacts with pSmad1 (top band). Immunoblotting for -actin was used to ensure equal loading. Black lines indicate that inter-
vening lanes have been spliced out. (e–g) Assessment of inhibition by RAP-041 of HUVEC tube formation (e) and spheroid sprouting (f; analyses  
independently performed at least three times) and VEGF- and FGF-induced vessels grown in subcutaneous Matrigel plugs (g; n = 5 mice per group).  
Error bars show the mean ± SD.JEM VOL. 207, January 18, 2010 
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(Fig. 4 a). Administration of an equivalent dose of RAP-041 
yielded a dramatic retardation of tumor growth, with a mean 
tumor burden of 8.9 ± 5.3 mm3 (Fig. 4 a, P < 0.001), which 
was comparable with that of the cohort sacrificed at the start 
of the trial (Fig. 4 a). To further characterize the efficacy of 
RAP-041, we performed a dose-response trial in which sepa-
rate  cohorts  of  10-wk-old  RIP1-Tag2  mice  were  treated 
with different doses of RAP-041 over the course of 2 wk. As 
seen in Fig. 4 b, the efficacy of RAP-041 improved with 
higher doses up to 12 mg/kg, after which a further increase 
Pharmacological inhibition of ALK1 signaling retards tumor 
growth in the RIP1-Tag2 model
To investigate the functional consequences of pharmacological 
inhibition of ALK1 signaling in tumors, we treated 10-wk-
old RIP1-Tag2 mice with RAP-041. Before the start of the 
trial, a separate cohort of RIP1-Tag2 mice was sacrificed to 
illustrate the initial tumor burden (Fig. 4 a). At the predefined 
conclusion of the trial after 2 wk of treatment, RIP1-Tag2 
mice treated with 12 mg/kg control Fc protein for a total of four 
doses presented with a mean tumor burden of 33.3 ± 24.1 mm3 
Figure 4.  Pharmacological inhibition of ALK1 signaling retards tumor growth in the RIP1-Tag2 model. (a) Quantification of the total tumor 
burden of RIP1-Tag2 mice at 10 wk of age or after a 2-wk treatment with 12 mg/kg control Fc protein or RAP-041. (b) RAP-041 dose-response curve upon 
intraperitoneal injection of 1–24 mg/kg for 2 wk (10–12 wk of age). To allow a direct comparison, data for the cohort aged 10 wk, the control Fc cohort, 
and the 12-mg/kg cohort have been duplicated from a. (c) Quantification of the total tumor burden of RIP1-Tag2 mice at 12 wk of age or after a 2-wk 
treatment with 12 mg/kg of control Fc protein or RAP-041. Error bars show the mean ± SD.92 Targeting of ALK1 impairs tumor growth | Cunha et al.
VEGF-A did not elicit a proliferative response of any of the 
endothelial cell lines (Fig. 6 a and Fig. S5, a–c). We found 
that the proliferation of all three cell lines was significantly 
retarded by either TGF- or BMP9 alone, compared with 
untreated control cells (Fig. 6 a and Fig. S5, a–c). However, 
in sharp contrast, TGF- together with BMP9 enhanced the 
mitogenic response of endothelial cells in response to VEGF-A 
in all cases (Fig. 6 a and Fig. S5, a–c).
Next, we investigated the effects of joint stimulation with 
TGF- and BMP9 on VEGF-A and bFGF-induced angio-
genesis in vivo. Matrigel plugs containing VEGF-A/bFGF with 
or without the supplement of TGF- and BMP9 were injected 
subcutaneously into mice. Although TGF- and BMP9 by 
themselves did not give rise to an angiogenic response, the 
addition of the two ligands significantly improved the ingrowth 
of blood vessels induced by VEGF-A and bFGF (Fig. 6, b and c, 
P < 0.001), an outcome which was effectively reverted by 
RAP-041 (Fig. 6, b and c, P < 0.001).
Angiogenesis in tumors from RIP1-Tag2 mice is crucially 
dependent on VEGF-A (Inoue et al., 2002). The effects of 
TGF- and BMP9 on endothelial cell growth, as well as the 
observed synergy with VEGF-A in vitro and in vivo, led us to 
perform further experiments using a functional ex vivo model 
of angiogenic chemotaxis and sprouting in the RIP1-Tag2 
model. We purified angiogenic islets from 12-wk-old RIP1-
Tag2 mice by collagenase dissociation followed by Ficoll gra-
dient separation. Next, the angiogenic islets were seeded into 
Matrigel plugs containing MS1 cells and overlaid with serum-
free medium containing combinations of TGF-, BMP9, and 
RAP-041. Angiogenesis-modulating factors produced by the 
islets will diffuse into the Matrigel and affect the phenotype 
and behavior of the resident endothelial cells. Under the con-
ditions used, very little migration of endothelial cells from the 
angiogenic islets into the Matrigel was observed (unpublished 
data). When left untreated or treated with control Fc protein, 
the MS1 cells migrated and sprouted radially toward the angio-
genic islet, demonstrating the net production of pro-angiogenic 
factors by the explanted tumor tissue (Fig. 6, d and e; and not 
depicted). Strikingly, the addition of RAP-041 to the ex vivo 
culture inhibited baseline migration and sprouting by 56%, 
indicating that BMP9 was required for efficient angiogenesis 
in response to the islet-produced factors, most notably VEGF-A 
(Fig. 6, d and e, P < 0.05). The exogenous addition of TGF- 
or BMP9 alone blocked the radial in-growth of endothelial 
cells toward the angiogenic islet (Fig. 6, d and e, P < 0.01 and 
P < 0.05, respectively). In sharp contrast, the combined ex-
ogenous action of TGF- and BMP9 negated the inhibitory 
effects of each ligand alone (Fig. 6, d and e, P < 0.001 vs. either 
factor alone and P > 0.5 vs. control). In the presence of both 
TGF- and BMP9, RAP-041 again reduced the endothelial 
cell sprouting and migration, leaving the MS1 cells disordered 
on the edge of the angiogenic islet (Fig. 6, d and e, P < 0.001). 
Collectively, our findings demonstrate an unexpected synergy 
through which combined stimulation of endothelial cells with 
TGF- and BMP9 negates the angiostatic effects of each li-
gand alone and prime endothelial cell to the pro-angiogenic 
to 24 mg/kg did not result in a more favorable outcome. 
RAP-041 was well tolerated and no overt adverse effects 
were observed (unpublished data).
Next, we performed a therapeutic trial at a later stage of 
tumor development to investigate whether RAP-041 also in-
hibited the growth of established bulky tumors. RIP1-Tag2 
mice were treated with four injections of 12 mg/kg RAP-041 
from 12–14 wk of age. In contrast to mice treated with control 
Fc protein, which displayed an increased mean tumor burden 
compared with a cohort of 12-wk-old mice, mice that received 
RAP-041 did not show a significant growth in their mean 
tumor burden during the course of the trial (Fig. 4 c; P < 0.05). 
We conclude that administration of the ALK1-Fc fusion protein 
RAP-041 dramatically retards tumor growth in RIP1-Tag2 
mice, both at early and late stages of tumor development.
Treatment with RAP-041 impairs tumor angiogenesis in vivo
We characterized the effects of administration of RAP-041 
on the phenotype of RIP1-Tag2 tumors. Tumors from mice 
treated with RAP-041, regardless of the tumor stage at the 
time of treatment, displayed a diminished vascular density 
and perfusion compared with tumors from control-treated 
mice (Fig. 5, a and b, vascular density, P < 0.0001 at 12 wk, 
P < 0.001 at 14 wk, and perfusion, P < 0.001). In addition, 
blood vessels in tumors from mice exposed to RAP-041 
exhibited increased pericyte coverage (Fig. 5 c; P < 0.05). 
Although no significant difference in proliferative index was 
noted, the malignant  cells demonstrated a higher apoptotic 
index in tumors from mice treated with RAP-041, compared 
with tumors from control-treated mice (Fig. 5 d, P < 0.05; 
and not depicted). This is most likely the result of secondary 
effects  from  the  anti-angiogenic  phenotype  because  treat-
ment of the established RIP1-Tag2 tumor cell line TC3 
with  RAP-041  in  vitro  affected  neither  proliferation  nor 
apoptosis (Fig. S4, a and b). Collectively, our findings indi-
cate that RAP-041 inhibits tumor angiogenesis in vivo, thus 
limiting tumor growth by promotion of apoptosis.
Combined stimulation with TGF- and BMP9 enhances  
the endothelial cell response to angiogenic stimuli
To elucidate the molecular mechanism behind the observed 
tumor growth inhibition by RAP-041, we performed a series 
of studies examining endothelial cell function in the context 
of an angiogenic stimulus. Importantly, both TGF- and BMP9 
were present at progressively elevated levels in RIP1-Tag2 
lesions in vivo (Fig. 1 a), prompting us to investigate how the 
presence of both ligands affects an angiogenic response. First, 
we made use of three different endothelial cell lines (the MS1 
mouse pancreatic islet endothelial cell line [Arbiser et al., 
1997], human telomerase-immortalized microvascular endo-
thelial cells [Venetsanakos et al., 2002], and the mouse brain 
endothelial cell line bEND.3) to investigate the effects of 
TGF- and BMP9 signaling on endothelial cell proliferation 
(the mean measurement of all three cell lines is depicted in 
Fig. 6 a, whereas measurements for the individual cell lines 
are found in Fig. S5, a–c). At the chosen dose, treatment with JEM VOL. 207, January 18, 2010 
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Figure 5.  Treatment with RAP-041 impairs tumor angiogenesis in vivo. (a and b) Quantification of the vascular density by CD31 immunostaining 
(a) and by FITC-lectin perfusion (b) as a percentage of the lesional area, both in tumors from control Fc or RAP-041–treated mice of indicated age.  
(c) Quantification of pericyte coverage (number of NG2+ cells divided by number of CD31+ cells) of the vessels, as a percentage of the lesional area, of 
tumors from control Fc or RAP-041–treated mice. (d) Apoptotic index of tumors from control Fc or RAP-041–treated mice. n = 5 mice for each analysis; 
10–15 high-power fields were scored for each mouse. Error bars show the mean ± SD. Bars, 50 µm.94 Targeting of ALK1 impairs tumor growth | Cunha et al.
Figure 6.  BMP9 and TGF- synergistically regulate endothelial cell function. (a) Quantification of the proliferative index of endothelial cells (pre-
sented as a mean for the three endothelial cell lines MS1, bEND.3, and TIME) as a percentage of Ki67 positively stained cells over the total number of cells 
upon no treatment or addition of different treatments with TGF-, BMP9, VEGF-A, and combinations thereof. (b) Immunostaining for the endothelial cell 
marker CD31 (brown) of subcutaneously injected Matrigel plugs containing VEGF-A + bFGF, TGF- + BMP9, RAP-041, and combinations thereof.  
(c) Quantification of the vascular ingrowth, as calculated by CD31 immunostaining in subcutaneously injected Matrigel plugs containing the factors indi-
cated. (d) Ex vivo co-culture of RIP1-Tag2 angiogenic islets and MS1 endothelial cells on Matrigel upon absence or presence of treatment with TGF-, 
BMP9, RAP-041, and combinations thereof. All analyses were independently performed at least three times. (e) Quantification of the area covered by  
migrating/sprouting endothelial cells bordering the angiogenic islet. Each mean represents quantification of five to eight angiogenic islets per condition. 
Error bars show the mean ± SD. Bars, 50 µm.JEM VOL. 207, January 18, 2010 
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BMP9 on the protein level (Fig. 7 e). Finally, we investigated 
whether the increased expression of PAI-1 was accompanied 
by enhanced upstream activation of TGF-–induced signaling 
pathways. Indeed, combined stimulation of MS1 cells with 
TGF- and BMP9 potentiated the activation of Smad2, as as-
sessed by Western blot analysis using phospho-specific anti-
bodies (Fig. 7 e). Thus, we have demonstrated that both ALK1 
and ALK5 target genes are affected by genetically or pharma-
cologically diminished ALK1 signaling and that TGF- and 
BMP9 synergistically induce ALK5 target genes, most likely 
through a Smad2-dependent pathway.
DISCUSSION
There is ample evidence from genetic studies that signaling by 
TGF- family members plays an important role in angiogen-
esis. Deletion of either of the genes coding for TGF-1, 
ALK1, ALK5, TGF-RII, Smad5, or endoglin in mice yields 
embryonic lethality as a result of various defects in the vascular 
tree (ten Dijke and Arthur, 2007). In the case of ALK1, the 
angiogenic defects are endothelial cell autonomous because a 
selective endothelial cell knockout mouse line recapitulates 
the global gene knockout phenotype (Park et al., 2008). In 
contrast, conditional knockout of the genes for ALK5 or 
TGF-RII in endothelial cells did not result in overt vascular 
malformations (Park et al., 2008). We clearly demonstrate that 
Alk1 is a haploinsufficient gene in the context of tumor angio-
genesis. RIP1-Tag2; Alk1+/ mice displayed a reduction in 
the number of angiogenic islets, as well as a reduced total 
tumor burden. However, there is great variation in the con-
clusions drawn from in vitro studies of the role of TGF- in 
endothelial cell function in different contexts. As an example, 
low concentrations of TGF- appear to enhance endothelial 
cell function in angiogenesis, whereas high concentrations of 
TGF- result in opposite effects (Goumans et al., 2003a). 
One model to explain the apparent duality of TGF- in endo-
thelial cell biology is based on the fact that negative regula-
tory signals derived from TGF-–induced ALK5 activation is 
more persistent than positive regulatory signals stemming from 
TGF-–induced ALK1 activation (Goumans et al., 2003a). In 
this paper, we find that TGF- by itself reduced endothelial 
cell proliferation and inhibited endothelial cell sprouting in an 
ex vivo culture of angiogenic pancreatic islets. In agreement 
with published results (David et al., 2007; Scharpfenecker et al., 
2007), BMP9 negatively regulated endothelial cell functions 
to a similar degree as TGF-. However, TGF- and BMP9 
do not act in isolation in vivo. Motivated by expression analyses 
demonstrating dramatically increasing levels of both TGF- 
and BMP9 during the RIP1-Tag2 tumor progression pathway, 
we stimulated endothelial cells with both factors simultane-
ously. Surprisingly, the two ligands acting in concert negated 
the negative effects of each ligand alone and enhanced the re-
sponse  of  endothelial  cells  toward  VEGF-A  and/or  bFGF 
both in vitro and in vivo. These observations provide an alter-
native explanation for the discrepancies between different 
studies of TGF- in endothelial cell function because the 
presence or absence of BMP9 in distinct experimental settings 
action of VEGF-A and bFGF, a synergy which was effec-
tively abrogated by RAP-041 both in vitro and in vivo.
Expression of target genes for both ALK1 and ALK5 are 
down-regulated by blunted ALK1 signaling
To elucidate the molecular mechanism behind the observed 
angiogenic effects of TGF- and BMP9 signaling, we examined 
the expression of known target genes with pro-angiogenic 
properties for ALK1 (inhibitor of differentiation [Id] 1, 2, and 3) 
and ALK5 (plasminogen activator inhibitor [PAI] 1, PDGF-B, 
and fibronectin; Goumans et al., 2002; David et al., 2007). 
All target genes examined were found to be dramatically up-
regulated  in  RIP1-Tag2  angiogenic  islets  and/or  tumors, 
compared with normal islets (Fig. S6, a–d; and not depicted), 
which is consistent with our observation that TGF- and 
BMP9 were similarly induced during tumor progression.   
Expression analysis using mRNA from isolated endothelial cells 
from RIP1-Tag2 tumors revealed that Id1 was exclusively 
expressed by endothelial cells, whereas Id3 exhibited some 
expression also by other cell types (Fig. S6, e and f). Similarly, 
the prototypical ALK5 target genes PAI-1 and PDGF-B were 
predominantly expressed by endothelial cells, as ascertained 
by immunostaining (Fig. S6, g and h). Notably, either dimi-
nution of ALK1 gene dosage or treatment with RAP-041 
gave rise to a lower expression level of Id1 and Id3 in tumors 
(Fig. 7, a and b). Surprisingly, tumors from RIP1-Tag2; Alk1+/ 
mice or from RIP1-Tag2 mice treated with RAP-041 exhibited 
reduced expression of PAI-1, indicating that ALK1 signaling 
affects also ALK5 target gene expression in vivo (Fig. 7 c).
We went on to appraise the transcriptional activation 
downstream of ALK1 and ALK5 receptors after combined 
ligand stimulation of cultured cells using promoter-driven lu-
ciferase constructs. Dual stimulation with TGF- and BMP9 
did not result in an increased activation of ALK1-driven tran-
scription (Fig. S7 a). In contrast, joint signaling by TGF- and 
BMP9 synergistically induced transcriptional activation of the 
ALK5 target gene promoter construct in transfected MS1 cells 
(Fig. S7 b, P < 0.01). Next, we sought to investigate whether 
the induction of pro-angiogenic ALK5 target genes in endo-
thelial cells was altered after stimulation with both TGF- and 
BMP9. Indeed, although TGF- induced PAI-1 mRNA in 
MS1 mouse pancreatic islet endothelial cells and BMP9 had 
no appreciable effect, the PAI-1 mRNA was synergistically 
induced by combined treatment with TGF- and BMP9 
(Fig. 7 d, P < 0.001), which is consistent with the finding that 
TGF- and BMP9 cooperatively activated the ALK5 target 
gene promoter construct. Similar results for PAI-1 were ob-
tained using the brain endothelial cell line bEnd.3 (Fig. S7 c) 
and for induction of the ALK5 target gene PDGF-B in MS1 
cells (Fig. S7 d, P < 0.001). Intriguingly, the synergistic in-
duction of PAI-1 by TGF- and BMP9 required both ALK1 
and ALK5 receptors, as indicated by the use of RAP-041 and 
the kinase inhibitor SB431542 to selectively inhibit signaling 
from ALK1 and ALK5, respectively (Fig. 7 d). Western blot 
analysis of lysates from MS1 cells further corroborated the 
synergistic induction of PAI-1 expression by TGF- and 96 Targeting of ALK1 impairs tumor growth | Cunha et al.
Figure 7.  Both ALK1 and ALK5 target gene expression is down-regulated by blunted ALK1 signaling. (a–c) Id1 (a), Id3 (b), and PAI-1 (c) mRNA 
expression in tumors from RIP1-Tag2; Alk1+/ mice compared with that of WT littermates at 12 wk of age, as well as RIP1-Tag2 mice treated with control Fc 
(Ctrl Fc) protein or RAP-041 between 10 and 12 wk of age. The values for each gene represent mean and SD of at least three independent experiments with 
three to seven tumors per experimental condition. (d) Expression of PAI-1 mRNA in MS1 endothelial cells treated with TGF-, BMP9, RAP-041, SB431542, 
and combinations thereof. Error bars show the mean ± SD. (e) Western blot analysis of PAI-1 protein levels and phosphorylated Smad2 (pSmad2) levels in 
lysates from MS1 cells subjected to single or combined stimulation of TGF- and BMP9. Relative expression levels were calculated by densitometric quanti-
fication of PAI-1 or pSmad2 relative to the reference protein calnexin. All analyses were independently performed at least three times.JEM VOL. 207, January 18, 2010 
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bFGF-induced growth and sprouting. The exact nature of 
the cross talk between ALK1, ALK5 and VEGF receptor sig-
naling pathways warrants further investigations.
Clinical benefit from targeted therapeutics aimed at the 
VEGF pathway has been demonstrated in several malignancies 
including colon, renal, lung, and breast carcinoma. Although 
providing a measurable prolongation of time to progression 
and, in some cases, also survival, most treatment regimens in-
corporating novel vascular targeting agents amount to a minor 
benefit measured in months (Hurwitz et al., 2004; Escudier 
et al., 2007; Motzer et al., 2007). Moreover, recent preclinical 
data provide evidence for the development of resistance and 
the emergence of more aggressive and invasive tumors after 
anti-angiogenic treatments (Bergers and Hanahan, 2008; Pàez-
Ribes et al., 2009). It is likely that, as in the case of conven-
tional chemotherapeutic drugs, combinations of different 
anti-angiogenic agents will be needed to produce long-lasting 
objective responses. ALK1 inhibitors are now making their ap-
pearance in clinical trials, as exemplified by ACE-041, the 
human counterpart of RAP-041, and PF-3446962, a humanized 
monoclonal antibody. Early phase clinical studies will have to 
determine which malignancies are most sensitive to ALK1 in-
hibition. Regardless of which patient group will be treated, 
however, our findings mandate that molecular profiling of the 
expression of ligands and receptors should be implemented be-
fore treatment as part of the study protocol. Our studies using 
both genetic and pharmacological means identify ALK1 as an 
attractive target for inhibiting angiogenesis in cancer. Drugs 
blocking ALK1 may thus be a valuable constituent in the con-
certed arsenal against tumor vascularization and growth.
MATERIALS AND METHODS
Quantitative RT-PCR. Total RNA was isolated using the RNeasy mini-
kit (QIAGEN), after which 1 µg of total RNA served as template for RT 
using the iScript cDNA Synthesis kit (Bio-Rad Laboratories). Quantitative 
PCR was performed with an annealing temperature of 58°C on a Rotor-
Gene 6000 (QIAGEN) in triplicate samples using the QuantiMix SYBR 
green kit (BioTools) and 1 µl of template from the RT reaction. Expression 
levels were calculated relative to expression of the reference ribosomal gene 
RPL19, as calculated by the formula 100*2Ct. Isolated RNA from normal 
islets and from different stages of RIP1-Tag2 tumor progression was pro-
vided by P. Olsen and D. Hanahan (University of California, San Francisco, 
San Francisco, CA).
Primers used for quantitative RT-PCR. A list of the primers used for 
quantitative RT-PCR is shown in Table I.
Immunostaining. Cryosections were fixed with acetone. After blocking 
using serum-free protein block (Dako) for 90 min at room temperature (for 
PAI-1 staining, the Mouse-on-mouse immunodetection kit [Vector Labora-
tories] was used), sections were incubated overnight at 4°C with primary 
antibodies directed against BMP9 (ab35088; dilution, 1:500; Abcam), TGF- 
(sc-146; dilution, 1:500; Santa Cruz Biotechnology, Inc.), ALK5 (AF3025; 
dilution,  1:25;  R&D  Systems),  CD31  (MEC13.3;  dilution,  1:100;  BD), 
PAI-1 (Clone 41; dilution, 1:100; BD), or NG2 (AB5320; dilution, 1:400; 
Millipore) in PBS supplemented with 1% BSA. After three washes, sections 
were incubated with appropriate secondary antibodies (Invitrogen), washed, 
and mounted in DAPI-containing medium (Vector Laboratories).
Paraffin-embedded sections were deparaffinized followed by antigen re-
trieval in 0.25 mg/ml trypsin-EDTA in PBS at 37°C for 30 min. Blocking was 
would yield opposing results. Interestingly, TGF- and BMP7 
synergistically stimulate angiogenesis in the chick chorio-
allantoic membrane assay (Ramoshebi and Ripamonti, 2000), 
and BMP7 potentiates TGF-–induced activation of the 
E-cadherin promoter in prostate cancer cells (Buijs et al., 2007).
Blunted ALK1 signaling in the context of RIP1-Tag2 
tumorigenesis gave rise to molecular changes in the expression 
of key regulators of angiogenesis that are characteristic for 
TGF- signaling. As expected, tumors deficient for one copy 
of the gene encoding ALK1 exhibited diminished expression 
of Id1 and Id3, which is consistent with previous studies es-
tablishing these genes as specific targets of ALK1 signaling 
(Goumans et al., 2002). Notably, expression of Id1 and Id3 is 
required for tumor angiogenesis to occur (Lyden et al., 1999). 
Unexpectedly, the expression of the ALK5-specific target 
gene PAI-1 was also altered in RIP1-Tag2; Alk1+/ mice, 
giving further support to earlier studies demonstrating that 
ALK1 and ALK5 signaling is interdependent (Goumans et al., 
2003b). Moreover, combined treatment of endothelial cells 
with TGF- and BMP9 synergistically induced PAI-1, which 
is suggestive of a causal relationship between PAI-1 and the 
cooperative angiogenic effects of dual ALK1 and ALK5 acti-
vation. Even though there are results reporting cytostatic and 
antimigratory properties of PAI-1 in fibroblasts (Deng et al., 
1996; Kortlever et al., 2006; Kortlever et al., 2008), a recent 
study using PAI-1–deficient mice convincingly demonstrates 
that tumors devoid of host-derived PAI-1 are very poorly 
vascularized as a result of increased endothelial cell apoptosis 
(Bajou et al., 2008). Together with the observed reduction of 
VEGF-induced angiogenesis after ALK1 inhibition, diminished 
expression of Id1, Id3, and PAI-1 is a likely contributing cause 
for the stunted angiogenic response in RIP1-Tag2; Alk1+/ 
mice. However, we do not exclude that there may be addi-
tional causal effects of blunted ALK1 expression or signaling.
Treatment of WT RIP1-Tag2 mice with optimal doses 
of RAP-041 yielded a near identical phenotype to that of 
RIP1-Tag2; Alk1+/ mice. Also, the molecular efficacy of 
RAP-041 in terms of diminishing expression of the target 
genes Id1, Id3, and PAI-1 appeared analogous to the genetically 
perturbed ALK1 pathway. Thus, because RAP-041 does not 
neutralize TGF-, it is likely that BMP9 and/or BMP10 is the 
physiological ligand acting through ALK1 during RIP1-Tag2 
tumorigenesis. Importantly, by blocking BMP9, RAP-041 
reveals the anti-angiogenic effects of TGF- without inter-
fering with possible tumor suppressive functions that TGF- 
may have in other contexts within the tumor. The therapeu-
tic benefit from treatment with RAP-041 is comparable to 
that of specific inhibitors of the VEGF pathway, as observed 
in similar trials using the RIP1-Tag2 mouse model (Bergers 
et al., 2003; Pietras and Hanahan, 2005). RAP-041 inhibited 
VEGF-A and bFGF-induced angiogenesis in Matrigel plugs, 
and both TGF- and other BMP family members, including 
BMP2, -4 and -6, have been demonstrated to regulate the ex-
pression of VEGF-A (Pertovaara et al., 1994; Deckers et al., 
2002; Suzuki et al., 2008). Moreover, stimulation with TGF- 
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of IgG1 and expressed in Chinese hamster ovary cells. RAP-041 was formu-
lated in 20 mM Tris-Hcl and 0.9% NaCl. The Fc domain of IgG1 was used 
as a control (IgG1 MOPC-21; Bio X Cell).
Cell culture. All cells were maintained at 37°C in a humidified atmosphere 
of 5% CO2 and in medium supplemented with penicillin and streptomycin. 
Endothelial cells were cultured on gelatin. HUVECs were kept in Medium 
199 with Earle’s salt and L-glutamine (Invitrogen), 20% FBS, heparin, and 
bovine pituitary extract (Invitrogen). MS1, TIME, and bEND.3 cells were 
cultured in an Endothelial Cell Basal Medium MV2 kit (Invitrogen). TC3 
and C2C12 cells were maintained in MEM and DME, respectively, (Invit-
rogen) supplemented with 10% FBS and L-glutamine.
Luciferase reporter assay. C2C12 or MS1 cells were transfected using   
Lipofectamine LTX (Invitrogen) with 0.2 µg pGL3(BRE)-luc (Korchynskyi 
and ten Dijke, 2002) or pGL3(CAGA)12-luc (Dennler et al., 1998) and 0.2 µg 
-gal construct to act as internal transfection control. After 24 h, cells were 
treated with 10 ng/ml TGF-, 10 ng/ml BMP9, or 50 ng/ml BMP10 in the 
presence or absence of 1 µg/ml RAP-041. Luciferase activity was deter-
mined after 24 h of stimulation.
Western blot analysis. For determination of RAP-041 specificity, HUVEC 
or C2C12 cells were starved for 5 or 24 h in medium with 1% FBS and stimu-
lated with BMP9 or TGF- for 45 min, washed with PBS, and lysed. For as-
sessment of phospho-Smad2 or PAI-1 levels, MS1 cells were starved overnight 
in medium containing 0.1% BSA and stimulated for 30 min and 48 h, respec-
tively. Protein concentration was quantified by DC protein assay (Bio-Rad 
Laboratories) and lysates were subjected to SDS-PAGE and Western blotting. 
Smad phosphorylation was detected with antiserum specifically recognizing 
phosphorylated Smad1/5 (Persson et al., 1998) or Smad2 (Piek et al., 1999), 
PAI-1 was detected using antibody ab28207 (Abcam), and calnexin levels were 
determined using sc-6465 (Santa Cruz Biotechnology, Inc.). Relative expres-
sion level was determined by densitometric quantification of PAI-1 or phos-
phorylated Smad2 corrected for the levels of calnexin for that particular lane.
HUVEC cord formation. Matrigel basement membrane matrix, growth 
factor reduced (BD), was added to a 96-well plate and allowed to polymerize 
for 1 h at 37°C. HUVECs (3 × 103 cells/well) were resuspended in Medium 
199 containing 4% FBS and 10 µg/ml RAP-041, 10 µg/ml control Fc, or 
vehicle control and seeded in triplicates. Plates were incubated for 16 h. Pic-
tures were acquired with a phase-contrast microscope in four different fields. 
The length of branches was quantified using automated image analysis using 
Analysis software (Olympus).
HUVEC spheroid sprouting assay. The endothelial sprouting assay was per-
formed as described previously (Hawinkels et al., 2008). Spheroids (750 cells/
well) were prepared by culturing HUVEC in complete medium containing 
0.1% methylcellulose. The next day spheroids were collected and embedded in 
a collagen type 1 matrix and incubated with 50 ng/ml recombinant human 
VEGF (R&D Systems) with addition of control Fc protein or RAP-041.
Matrigel plugs. Male 7–8-wk-old C57BL/6 mice (Charles River Labora-
tories) were injected subcutaneously near their abdominal midline with 0.3 ml 
of Matrigel basement membrane at a high concentration (BD) combined 
with PBS, 2 ng/ml TGF-, 2 ng/ml BMP9, or 300 ng/ml VEGF and 700 ng/
ml bFGF-2 in the presence or absence of 20 µg/ml RAP-041 or 20 µg/ml 
of control Fc protein. Groups of four plugs were injected for each treat-
ment and the experiment was repeated twice. 7 d later, Matrigel plugs were 
removed, fixed in formalin, and embedded in paraffin. Sections were depar-
affinized.  Quenching  of  endogenous  peroxidase  activity  was  done  using 
0.3% H2O2 in methanol for 20 min at room temperature, followed by anti-
gen retrieval using citrate buffer and blocking with 1% BSA in PBS for 1 h 
at room temperature. The primary antibody against CD31 (1:1,000; Santa 
Cruz Biotechnology, Inc.) was incubated in 1% BSA in PBS overnight at 
room temperature. Biotinylated conjugated secondary antibodies were ap-
plied, followed by amplification using the strep-AB-complex/HRP (Dako). 
performed in 1% BSA and 0.5% Tween-20 in PBS. The primary antibodies 
against ALK1 (HPA007041; dilution, 1:100; Atlas Antibodies) and podoca-
lyxin (AF1556; dilution, 1:100; R&D Systems) were incubated in 0.5× block-
ing buffer overnight at 4°C, after which appropriate secondary antibodies 
(1:100) were incubated in 0.5× blocking buffer for 2 h at room temperature.
Microscope image acquisition. Imaging was performed using a micro-
scope (Eclipse E800; Nikon) equipped with Plan Fluor objectives (10×, 0.30 
NA; 20×, 0.50 NA; 40×, 0.75 NA; Nikon) at room temperature in air using 
Alexa 594– and Alexa 488–coupled secondary antibodies. Images were ac-
quired using a SPOT RTKE camera using the SPOT advanced software 
(Diagnostic Instruments, Inc.).
Animal care. All animal studies described were approved by the Stockholm 
north committee for animal experimentation. From 12 wk of age, all RIP1-
Tag2 mice received 30% sugar water to relieve hypoglycemia. ALK1+/ 
mice were provided by S.P. Oh (University of Florida, Gainesville, FL).
Assessment of angiogenic islets and tumor incidence. Angiogenic is-
lets were counted under a dissection microscope and defined as overtly red   
islets of <1 × 1 mm within the pancreas. Tumors were defined as >1 × 1 mm   
and were excised and measured with calipers. Volume was calculated using   
the formula /6 × length × width2.
Quantification of vascular density and perfusion. Vessel density was 
measured as the total number of positively stained pixels within at least eight 
high-power fields per mouse. Perfused functional vessels were assessed by 
systemic vessel labeling with FITC-conjugated tomato lectin (Vector Labo-
ratories) injected 4 min before euthanasia.
RAP-041. RAP-041 (Acceleron Pharma) is a fusion protein comprised of 
aa 22–117 of the extracellular domain of mouse ALK1 fused to the Fc region 
Table I.  List of primers used for quantitative RT-PCR
Gene 5–3 Direction
RPL19 GGTGACCTGGATGAGAAGGA Forward
RPL19 TTCAGCTTGTGGATGTGCTC Reverse
ALK1 TGACCTCAAGAGTCGCAA Forward
ALK1 CTGGGGTGCCATGTATCTTT Reverse
ALK5 CAGAGGGCACCACCTTAAAA Forward
ALK5 CTCGCCAAACTTCTCCAAAC Reverse
BMP9 AACGGACAAATCGTCTACGC Forward
BMP9 TGTGCTTCTGAAAGGGGAAG Reverse
TGF- TGCTTCAGCTCCACAGAGAA Forward
TGF- TGGTTGTAGAGGGCAAGGAC Reverse
Endoglin CACAACAGGTCTCGCAGAAA Forward
Endoglin GCTTGGATGCCTGAAGAGTC Reverse
Id1 GAGTCTGAAGTCGGGACC Forward
Id1 TTTTCCTCTTGCCTCCTGAA Reverse
Id3 ACTCAGCTTAGCCAGGTGGA Forward
Id3 GTCATGGGCAAAAGCTCCTC Reverse
PAI-1 TGCATCGCCTGCCATT Forward
PAI-1 CTTGAGATAGGACAGTGCTTTTTCC Reverse
PDGF-B CCTCGGCCTGTGACTAGAAG Forward
PDGF-B CCTTGTCATGGGTGTGCTTA Reverse
CD31 AGAGACGGTCTTGTCGCA Forward
CD31 TACTGGGCTTCGAGAGCATT Reverse
VE-cadherin CAATGACAACTTCCCCGTCT Forward
VE-cadherin CGTTTGGGGTCTGTCTCAAT ReverseJEM VOL. 207, January 18, 2010 
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